



H ydrochlorothiazide (HCTZ) is a thiazide diuretic that blocks the specific sodium transport in the nephron; it is mainly used for the treatment of 
edema, arterial hypertension, congestive heart failure, 
and several forms of renal and hepatic dysfunctions(1). It 
is administered orally, at doses of 25 and 50 mg in tablet 
form (2).  
There is not agreement in the classification criterion of 
HCTZ, according to the Biopharmaceutical Classification 
System (BCS) (3). Some authors consider it as a Class IV 
or II drug (4, 5). However, most authors classify HCTZ as 
a Class III drug (i.e., high solubility and low permeability) 
(3, 6–8). 
In Argentina, HCTZ tablets are available both as reference 
and multisource products; however, it is a common 
practice that patients replace not only the reference 
with multisource products, but also replace multisource 
products with the latest ones. It is important to point 
out that multisource products must have proven 
pharmaceutical equivalence with the reference. 
To establish that products containing the same amount 
of active pharmaceutical ingredient (API) (in the same 
pharmaceutical form and designed to be administered by 
the same route) are pharmaceutical equivalents, it must 
be verified that all of them comply with quality standards, 
such as identity, potency, dose uniformity, dissolution test 
and profile, and information regarding storage conditions 
(9, 10).
In vitro dissolution testing is an economic and useful tool 
to assure product quality, and to estimate pharmaceutical 
equivalence to the reference product (11). The point 
estimate approach is suitable for products containing 
APIs with high solubility-high permeability, but it may not 
be adequate for low solubility or low permeability ones. 
In these situations, products with inherently different 
dissolution profiles may sometimes comply with the 
point estimate given as a pharmacopeia standard. This, in 
turn, may inadvertently lead to the declaration of similar 
dissolutions. Dissolution profile comparison seems to 
be more precise than the point estimate approach for 
accurate characterization of the drug product (12, 13).
This study aimed to evaluate the quality and 
pharmaceutical equivalence of commercial products 
containing HCTZ (50 mg) marketed in Argentina, based 
on local Pharmacopeia guidelines. 
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ABSTRACT
Hydrochlorothiazide (HCTZ) is a diuretic used to treat hypertension, which belongs to Class III of the Biopharmaceutics 
Classification System. The present study aimed to evaluate critical quality parameters of HCTZ solid oral dosage forms on 
the Argentine pharmaceutical market. For this purpose, evaluation of labels and patient information leaflets, description 
and mean weight of tablets, uniformity of dosage units, assay, hardness, friability, disintegration and dissolution tests 
were carried out, in compliance with the Argentine Pharmacopeia. The dissolution efficiency (DE) was obtained from 
the area under the drug dissolution curve, and the profiles were compared statistically by ANOVA. All samples met 
criteria for the assay, uniformity of dosage units, friability, hardness, disintegration tests, and dissolution test in Stage 
1. Sample D presented the lowest dissolution performance, in terms of DE values, with highly significant differences in 
comparison with the rest of the evaluated samples; however, the results of this study indicate that HCTZ tablets available 
in Argentina successfully pass all established quality control tests and can be considered pharmaceutical equivalents. 








HCTZ was purchased from Saporiti (Parafarm, Argentina). 
Analytical grade sodium hydroxide and hydrochloric acid 
were used in the assay, uniformity of dosage units and 
dissolution tests (Anedra, Argentina).
Tablet Samples
Four different HCTZ (50-mg) tablets were purchased 
at pharmacies in Bahia Blanca, Argentina. Tablets were 
randomly labeled as A to D. Reference product was 
Sample B; and A, C and D were multisource products.
Equipment
A Varian Cary 50 Conc spectrophotometer (Varian 
Instruments, Australia) was used for assay and dissolution 
studies. Hardness of the tablets was measured using a Scout 
DGM02 hardness tester (Scout Electronics, Argentina), 
friability via a Scout FGMO2, and disintegration with a 
Scout EGMO2. Dissolution studies were performed with 
an Erweka DT60 (Erweka GmbH, Germany). An Acculab 
ALC-210.4M electronic analytical balance (Acculab, USA) 
was used to weigh materials/chemicals and tablets.
Quality Control Tests
A comparative study of the information present on 
labels of primary and secondary packaging and in patient 
leaflets of the different samples was carried out to verify 
compliance with local legislation (14, 15).
For weight variation analysis, 10 tablets from each 
commercial sample were randomly chosen and 
individually weighed using an analytical balance. The 
mean weight and standard deviation (SD) were calculated. 
Friability, hardness, and disintegration tests were 
performed according to the Argentine Pharmacopeia 
(14). A friability test determines the ability of tablets to 
withstand abrasion during packaging, handling, and 
shipping processes. Ten tablets from each commercial 
sample were weighed separately, placed into the friability 
tester and rotated at 25 rpm for 4 min (100 revolutions). 
Then, the tablets were removed from the tester and 
weighed, comparing this result with the initial value. 
The weight loss due to abrasion was expressed as a 
percentage. A maximum weight loss of not more than 
1% is considered acceptable (14). The hardness of 10 
individual tablets of each sample was measured using a 
hardness tester, where the tablets  were placed between 
two platens, one of  which moved to apply s ufficient 
force to the tablet to cause fracture. This tester measures 
the  degree of force in kilopounds (kp) required to break 
a tablet across  the diameter.  Lastly, the  disintegration 
time of  tablets  (n = 6)  was  determined in  water at 
37.0 °C  ±  2.0  °C  using a  disintegration  tester.  After 
30 minutes, it  should  be observed  that  all tablets 
completely disintegrate, unless otherwise specified in the 
corresponding monograph (14). 
For HCTZ assay tests, 20 tablets were weighed and 
powdered. Then, an accurately weighed portion of 
the powder, equivalent to about 30 mg of HCTZ, was 
dissolved using 0.1 M sodium hydroxide and diluted 
to volume. The solution was filtered and diluted with 
water. Drug concentration was determined by UV-
spectrophotometry (272 nm) (16). The HCTZ content was 
calculated using a standard calibration curve (y = 0.0530 
x - 0.0133; R2 = 0.9998) developed for this purpose.
For uniformity of dosage units test, 10 tablets of each 
commercial sample were individually evaluated according 
to the assay method. 
Dissolution profiles were performed as recommended 
in the Argentine Pharmacopeia for dissolution quality 
control test, using sampling points of 5, 10, 15, 30, 45, 
60, and 75 minutes (14). Apparatus 1 (basket) at 100 rpm 
was used, with 900 mL of 0.1 M hydrochloric acid (HCl) 
as dissolution medium. At the specified times, 10-mL 
aliquots were taken, filtered through a 0.45-µm nylon 
membrane filter (Microclar, Argentina) and suitably 
diluted. The amount of HCTZ dissolved was calculated by 
comparing the measured  absorbance  at 272 nm  with  the 
calibration  curve prepared for  that  purpose.  A  standard 
calibration curve  of HCTZ  concentration  (μg/mL)  versus 
absorbance was  represented  by  the  linear  equation 
y = 0.0655x - 0.0005,  with   a  correlation coefficient 
of 0.9998 (concentration range 2.0–12.0 μg/mL). The 
Argentine Pharmacopeia indicates that not less than 
60% (Q) of the labeled amount of HCTZ should dissolve 
within 60 min (14). In addition, dissolution profiles were 
statistically evaluated, in terms of dissolution efficiency 
(DE), using analysis of variance (ANOVA, Infostat). DE was 
calculated as the ratio, in percentage, of the area under 
the curve obtained from the dissolution profile, with the 
total area of the rectangle considered as 100% dissolution 
for the same time interval (17).
RESULTS AND DISCUSSION
A comparative study of the information presented on 
labels (primary and secondary packaging) and patient 
leaflets of all products was performed based on 
World Health  Organization (WHO)  advice  and  local 
regulations (10, 14, 15). The concept of interchangeability 
is applicable not only to the API and to the pharmaceutical 
form, but also to the instructions for use and storage 
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specifications, especially when they are critical for 
stability and expiration date. Concerning packaging and 
storage conditions, the Argentine Pharmacopeia states 
to "preserve in well-closed containers" (14). The labels 
and leaflets of the tested samples revealed differences in 
storage recommendations (Table 1). Formulation A labels 
indicated to "store in its original packaging", whereas the 
other samples did not mention this factor. In addition, 
the label information did not match the one described in 
the leaflet. Products A, B, and D referred to a maximum 
storage temperature. It is important to point out that 
information included in labels and leaflets should be 
uniform across producers and controlled by regulatory 
agencies, so both patients and professionals can interpret 
them correctly. 
In Argentina, the widespread use of multisource products 
and interchangeability decisions taken by patients are 
generally based on economic reasons. Multisource HCTZ 
products exhibited similar price values, whereas the 
reference product was almost 40% higher (Table 1). This 
situation could lead to a misunderstanding about product 
quality. 
The results of physical quality control tests, performed as 
recommended by the Argentine Pharmacopeia, are shown 
in Table 1. The evaluation of weight values identified large 
differences between samples, with results ranging from 
149.4 to 250.6 mg. Differences in composition, typical 
of each manufacturer, and the physical dimensions of 
each product can explain this range of results, without 
necessarily being related to variations in the API content 
or dissolution performance. 
Another measure of the mechanical integrity of tablets 
is their breaking force, which is the force required to 
cause them to fail (i.e., break) in a specific plane, called 
hardness in the pharmaceutical literature. It is expected 
that no tablet have hardness results lower than 2.0 kp. 
The tablets were tested individually, and mean hardness 
values ranged between 3.5 and 10.7 kp for all tested 
products (Table 1). The friability test indicated very 
low loss of powder (< 0.5%), which complied with the 
maximum allowed value of 1% (14) (Table 1). The tested 
products also showed satisfactory disintegration results, 
between 28 and 360 sec (Table 1). Therefore, all samples 
met the official compendium requirement of 30 min 
disintegration (14). 
The HCTZ assay, uniformity of dosage units, and 
dissolution results are shown in Table 2. Assay results 
ranged from 93.6% ± 2.5% (Sample B) to 99.6% ± 1.4% 
(Sample A), and dissolution results were higher than 95% 
of labeled amount dissolved in 60 minutes for all samples, 
except for Sample D (values higher than 70%). Therefore, 
all formulations complied with the specifications of the 
Argentine Pharmacopeia for HCTZ content, uniformity of 
dosage units, and Stage 1 dissolution tests (14). 
Table 1. Information of Evaluated Products and Results of Physical Quality Control Tests 
Sample Pricea Storage conditions Tablet weight(mg)b
Hardness
(kp)b





B: Store in original packaging at room temperature, not 
greater than 30 °C.
L: Store below 30°C.
149.4 ± 2.8 3.5 ± 0.2 0.41 360
B (ref) 35.9 B and L: Store away from heat (not more than 30 °C). 199.5 ± 2.7 10.7 ± 0.8 0.17 210
C 22.0 B and L: Store in cool and dry room. 250.6 ± 2.4 5.5 ± 0.4 0.04 28
D 25.0 B and L: Store at a temperature below 30 °C. 161.1 ± 2.4 6.1 ± 0.3 0.31 95
aPrice in Argentine pesos at the time of analysis for 10 tablets. 
bMean value ± standard deviation.
cMaximum time needed for complete disintegration of evaluated tablets. 
B, labels; L, leaflets; kp, kilopound.
Table 2. Assay, Uniformity of Dosage Units, and Dissolution Test Results 








RSD < 6.0 60% (Q) in 60 min.
A 99.6 ± 1.4 [97.6–100.9] / 1.4 [97–105] / 2.7 86.8 ± 1.8
B (ref) 93.6 ± 2.5 [90.2–97.0] / 2.7 [97–99] / 0.8 93.0 ± 0.4
C 98.6 ± 4.1 [93.8–103.5] / 4.2 [101–105] / 1.6 90.8 ± 1.1
D 94.5 ± 1.9 [92.3–96.5] / 2.0 [71–79] / 4.5 66.5 ± 2.8
aPercentage of labeled amount. Mean value ± standard deviation.
bRange [minimum–maximum percentage of labeled amount] / relative standard deviation (RSD).
cRange [minimum–maximum percentage of labeled amount dissolved] /RSD.
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Figure 1 shows the dissolution profiles of HCTZ tablets 
in 0.1 M HCl, presented as mean percentages of labeled 
amount, associated with its corresponding standard 
deviation value. Dissolution profile analysis is an 
important tool to evaluate formulation development 
and marketed products, for batch quality control and 
establishing similarity between multisource and reference 
formulations. After 30 min, the dissolution profiles of 
the reference product B and multisource products A 
and C practically superimposed, indicating similar drug 
dissolution until the end of the test (Fig. 1). Samples 
B and C could be considered as ‘very rapid dissolution’ 
products, while Sample A revealed a ‘rapid dissolution’ 
performance (18). On the other hand, Sample D presented 
a significantly lower dissolution performance throughout 
the whole profile, with less than 85% dissolved (Fig. 1). 
DE was also used to assess HCTZ release and dissolution 
profile comparison. If a drug has a high DE, it can be 
inferred that the API remains in contact with physiologic 
membranes for a long time and, thus, could lead to greater 
bioavailability in the assessed concentration range. DE 
results were above 85% for Samples A–C, whereas Sample 
D exhibited the lowest values (Table 2). ANOVA revealed 
statistical differences between Sample D and the other 
products (p < 0.01). Moreover, no statistical differences 
were recorded between the reference product B and 
Sample C (p < 0.01). 
Several factors may influence dissolution results, such as 
the disintegration rate and the nature of the excipients. The 
use of excipients in HCTZ tablet composition is warranted 
due to being an immediate-release solid oral dosage form, 
ready to release the drug rapidly after administration. 
In these formulations, soluble diluents, disintegrating 
agents,  and/or other resources are  employed to 
promote disintegration, release, and dissolution (19, 20). 
By analyzing the excipients composition of the evaluated 
formulations, some observations can be made (Table 3). 
The reference formulation B contained lactose as diluent 
and  two disintegrants. The two  multisource formulations 
that achieved an  appropriate  release profile, products 
A and  C,  were  very  different in composition (Table 3, 
Fig. 1).  Product  A showed  four disintegrants,  associated 
with the soluble diluent lactose, which may be responsible 
for the adequate dissolution. Product C contained a 
single disintegrant associated with two diluents, lactose 
and cellulose. A previous study recommended avoiding 
formulations containing lactose and mannitol, because 
they are incompatible with HCTZ (21); however, our 
results are not in agreement with this observation 
because the formulations with better dissolution profiles 
(A, B and C) contained lactose, whereas product D had the 
lowest dissolution performance though it did not have 
this diluent. On the other hand, product D contained two 
disintegrants (povidone and croscarmellose), associated 
with a surfactant (sodium lauryl sulfate) and a diluent, 
such as microcrystalline cellulose (Table 3). These were all 
excipients that promote disintegration and dissolution. 
However, the dissolution profile of product D was not 
appropriate (Fig. 1). This could be related to the presence 
of the water-insoluble colorant (aluminum lake) or the 
method of manufacture (information not provided by the 
producer nor found in the literature).
Excipient type Sample
Excipient A B(ref) C D
Filler / Diluent
Lactose + + + -
Cellulose, 
microcrystallinea - - + +
Disintegrant
Corn starcha + + - -
Povidonea + + - +
Crospovidone + - - -
Croscarmellose 
sodium + - - +
Sodium starch 
glycolate - - + -
Glidant
Sodium lauryl 
sulphatea - - - +
Colloidal silicon 
dioxide - - + +
Lubricant Magnesium stearate + + + +
Colorant Aluminum lake - - - +
Figure 1.  Hydrochlorothiazide dissolution profile in 0.1 M HCl. Each line 
represents the mean percentage of labeled amount dissolved, associated 
with its corresponding standard deviation, for samples A–D (B, ref). Dotted 
line represents 85% dissolved level.
Table 3. Qualitative Composition of Excipients 




Multisource HCTZ tablets available in Argentina, together 
with the reference product, were subjected to analysis 
according to the Argentine Pharmacopeia. The results 
have shown that all the tested samples fulfilled the 
local requirements in terms of HCTZ content, friability, 
disintegration, uniformity of dosage units, and dissolution 
tests. Although one multisource product (Sample D) 
exhibited a lower dissolution performance, based on a 
reduced dissolution profile and DE results, it could be 
concluded that all evaluated products are pharmaceutical 
equivalents according to the Argentine Pharmacopeia. 
Further evaluation in relevant dissolution media will be 
performed to assess similarity and interchangeability of 
these formulations and their pharmaceutical stability.
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One of the most effective and 
reproducible way to test nano-
medicines, microformulations 
and semi-solid dosage forms. 
It’s „The German Gründlichkeit“.
The New Dispersion Releaser
The Dispersion Releaser PT-DR is a new dissolution apparatus to test the release of 
nanomedicines, microformulations and semi-solid dosage forms. It has been shown to be 
the most effective and reproducible way to test products with very low up to high solubility. 
The system consists of a donor and acceptor chamber which is surrounded by a membrane. 
Both chambers are agitated. This specific design allows controlling the shear forces applied 
to the nanoformulation. The PT-DR is compatible with all Pharma Test PTWS dissolution 
testers and also with each standard USP dissolution tester. 
